Nantkwest Inc (NASDAQ:NK)‘s stock had its “outperform” rating reiterated by analysts at FBR & Co in a note issued to investors on Friday. They currently have a $9.00 price objective on the stock, down from their prior price objective of $22.00. FBR & Co’s target price indicates a potential upside of 153.52% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research raised Nantkwest from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Saturday, November 19th. Jefferies Group LLC cut Nantkwest from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research note on Tuesday, January 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $12.90.
Shares of Nantkwest (NASDAQ:NK) opened at 3.55 on Friday. The company’s market capitalization is $292.43 million. Nantkwest has a 1-year low of $3.41 and a 1-year high of $10.26. The stock’s 50 day moving average price is $4.75 and its 200-day moving average price is $6.39.
Your IP Address:
Large investors have recently modified their holdings of the company. Tudor Investment Corp Et Al bought a new stake in Nantkwest during the fourth quarter worth approximately $102,000. Dynamic Technology Lab Private Ltd boosted its stake in Nantkwest by 96.6% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 21,474 shares of the company’s stock worth $123,000 after buying an additional 10,551 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in Nantkwest during the fourth quarter worth approximately $124,000. Renaissance Technologies LLC bought a new stake in Nantkwest during the fourth quarter worth approximately $140,000. Finally, Akanthos Capital Management LLC bought a new stake in Nantkwest during the third quarter worth approximately $205,000. 24.24% of the stock is currently owned by institutional investors.
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
Receive News & Ratings for Nantkwest Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest Inc and related companies with MarketBeat.com's FREE daily email newsletter.